| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-05-25 |
| タイトル |
|
|
タイトル |
Antiplatelets for Cardiovascular Disease in Non-valvular AF with Rivaroxaban: A Subanalysis of the EXPAND Study |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
キーワード |
Antiplatelet therapy |
| キーワード |
|
|
言語 |
en |
|
キーワード |
Bleeding |
| キーワード |
|
|
言語 |
en |
|
キーワード |
Non-valvular atrial fibrillation |
| キーワード |
|
|
言語 |
en |
|
キーワード |
Rivaroxaban |
| キーワード |
|
|
言語 |
en |
|
キーワード |
Stroke |
| 資源タイプ |
|
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
| 著者 |
海北, 幸一
WEKO
34072
e-Rad_Researcher
30346978
| ja |
海北, 幸一
宮崎大学
|
| ja-Kana |
カイキタ, コウイチ
|
| en |
Kaikita, Koichi
University of Miyazaki
|
Search repository
Uchiyama, Shinichiro
Atarashi, Hirotsugu
Inoue, Hiroshi
Kitazono, Takanari
| en |
Kitazono, Takanari
Graduate School of Medical Sciences, Kyushu University
|
Search repository
Yamashita, Takeshi
Shimizu, Wataru
| en |
Shimizu, Wataru
Graduate School of Medicine, Nippon Medical School
|
Search repository
Ikeda, Takanori
Kamouchi, Masahiro
| en |
Kamouchi, Masahiro
Graduate School of Medical Sciences, Kyushu University
|
Search repository
Fukuda, Koji
| en |
Fukuda, Koji
International University of Health and Welfare Hospital
|
Search repository
Origasa, Hideki
Shimokawa, Hiroaki
| en |
Shimokawa, Hiroaki
International University of Health and Welfare
|
Search repository
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Aim: In this subanalysis of the EXPAND study, we evaluated the risks and benefits of rivaroxaban plus antiplatelet therapy (APT) for patients with non-valvular atrial fibrillation (NVAF) complicated by stable coronary artery disease (CAD), ischemic stroke, or peripheral artery disease (PAD).
Methods: From the EXPAND study population (n=7,141), patients with NVAF complicated by stable CAD (n=886), ischemic stroke (n=1,231), or PAD (n=160) were included. Patients complicated by any of them were set as ALL (n=2,030). Patients were all treated with rivaroxaban (10 or 15 mg/day) with (+) or without (−) APT. Efficacy outcomes were symptomatic stroke＋systemic embolism (SE), symptomatic stroke＋SE＋myocardial infarction＋cardiovascular death, and all-cause death. Safety outcomes included major and any bleeding. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for differences between the APT(+) and APT(−) groups.
Results: There were no significant differences in the efficacy outcomes between the APT(+) and APT(−) groups in the ALL cohort or in the CAD and STROKE sub-cohorts. In the PAD subcohort, the HR [95% CI] for all-cause death in the APT(+) group increased (4.43 [1.05–18.71]; p=0.043). In the APT(+) group, the HR [95% CI] for any bleeding increased in the ALL cohort (1.28 [1.01–1.62]; p=0.044) and STROKE subcohort (1.42 [1.01–2.01]; p=0.047), and for major bleeding in the CAD subcohort (2.00 [1.01–3.93]; p=0.046).
Conclusions: Rivaroxaban with APT did not reduce ischemic outcomes in patients with stable CAD or ischemic stroke; however, it did increase the risk of bleeding in patients with stable CAD or ischemic stroke. |
|
言語 |
en |
| bibliographic_information |
ja : Journal of Atherosclerosis and Thrombosis
en : Journal of Atherosclerosis and Thrombosis
巻 32,
号 2,
p. 176-187,
発行日 2025-01-01
|
| 出版者 |
|
|
出版者 |
Japan Atherosclerosis Society |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
13403478 |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
18803873 |
| item_10001_relation_14 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.5551/jat.64681 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
fulltext (979 KB)
.png)
